Episode 35. Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson

Blood Cancer Talks

المحتوى المقدم من Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

9M ago 1:08:40

MP3•منزل الحلقة

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed:

1. Glofitamab for Relapsed/Refractory DLBCL:

https://pubmed.ncbi.nlm.nih.gov/36507690/

2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:

https://pubmed.ncbi.nlm.nih.gov/31451445/

3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:

https://pubmed.ncbi.nlm.nih.gov/36548927/

4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:

https://pubmed.ncbi.nlm.nih.gov/35803286/

5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:

https://pubmed.ncbi.nlm.nih.gov/35366963/

6. Epcoritamab + R2 in high-risk follicular lymphoma:

https://meetings.asco.org/abstracts-presentations/218265

7. Glofitamab in Mantle Cell Lymphoma:

https://ashpublications.org/blood/article/140/Supplement%201/178/489039

51 حلقات

#Fitness #Medicine #Rajshekhar Chakraborty and Ashwin Kishtagari #Ashwin Kishtagari #Rajshekhar Chakraborty #Hematology #Cancer #Podcasting Education #Edward Cliff